Free tool
FAERS Monitor: Omlyclo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761399 or its brand name (Omlyclo, Omalizumab-Igec). Reports on generic versions are filed under their own applications.
Reports
89
Serious
88
99% of reports
Hospitalization
13
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- urticaria20
- angioedema16
- pruritus16
- dyspnoea15
- malaise15
- asthma14
- product substitution issue13
- vomiting13
- cough12
- headache12
- pneumonia12
- wheezing12
- arthralgia10
- chest pain10
- dizziness10
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 1 |
| 2022 | 1 |
| 2025 | 5 |
| 2026 | 82 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,070 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| angioedemaSignal | 16 | 85.5 | 54.9 | 1,255 |
| product substitution issueSignal | 13 | 53.4 | 32.3 | 618 |
| wheezingSignal | 12 | 47.8 | 28.3 | 506 |
| asthmaSignal | 14 | 29.3 | 18.1 | 357 |
| urticariaSignal | 20 | 28.2 | 19.2 | 502 |
| chest painSignal | 10 | 12.8 | 7.1 | 98 |
| coughSignal | 12 | 10.1 | 6.0 | 91 |
| pruritusSignal | 16 | 9.8 | 6.3 | 121 |
| pneumoniaSignal | 12 | 8.8 | 5.2 | 76 |
| malaiseSignal | 15 | 8.1 | 5.1 | 88 |
| vomitingSignal | 13 | 6.5 | 4.0 | 57 |
| dyspnoeaSignal | 15 | 6.3 | 3.9 | 63 |
| arthralgiaSignal | 10 | 5.7 | 3.2 | 35 |
| dizzinessSignal | 10 | 4.7 | 2.6 | 27 |
| headacheSignal | 12 | 4.5 | 2.7 | 30 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.